Bryan Garnier Innovation Series: NK-based therapeutics
SAVE THE DATEApril 5th, 15:30 CETOur analysts Ingrid Gafanhão and Olga Smolentseva will be joined by Sanofi, Glycostem, XNK Therapeutics, Affimed, and Innate Pharma to discuss the present and future of NK-based therapies. Click the link to register, and stay tuned for the full agenda.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.